Riluzole
Oral Suspension · trading as Tiglutik
Current
FDA shortage record
- Substance
- Riluzole
- Brand name
- Tiglutik
- Manufacturer
- EDW PHARMA, INC
- Dosage form
- Oral Suspension
- Presentation
- Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)
- Route(s)
- ORAL
- Therapeutic category
- Neurology
- Package NDC
70726-0303-1- Initially posted
- 01/26/2024
- Current FDA status
- Current
Reason and context
Reason reported: Requirements related to complying with good manufacturing practices
EacNext release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 610-937-6172.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
75d68f19-4208-109e-e053-2991aa0ac857). - FDA UNII identifier:
7LJ087RS6F. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.